Chemetron Corp. v. UNITED STATES DEPT. OF HEALTH, ED. & W.
Decision Date | 24 January 1974 |
Docket Number | No. 72-1864,72-2217.,72-1864 |
Citation | 495 F.2d 995 |
Parties | CHEMETRON CORPORATION, a corporation, et al., Petitioners, v. The UNITED STATES DEPARTMENT OF HEALTH, EDUCATION AND WELFARE et al., Respondents. CHEMETRON CORPORATION, a corporation et al., Petitioners, v. The UNITED STATES DEPARTMENT OF HEALTH, EDUCATION AND WELFARE et al., Respondents. |
Court | U.S. Court of Appeals — District of Columbia Circuit |
Eugene I. Lambert, Washington, D. C., with whom Walter E. Byerley, Washington, D. C., was on the brief, for petitioners. Wayne K. Hill, Washington, D. C., also entered an appearance for petitioners Chemetron Corp. and Dawes Laboratories.
Howard S. Epstein, Atty. Dept. of Justice, with whom Peter Barton Hutt, Asst. Gen. Counsel, Health, Education and Welfare, Joanne S. Sisk, Chief, Appellate and Special Proceedings Branch, and Robert M. Spiller, Jr., Atty. Food, Drug and Product Safety Division, Health, Education and Welfare, were on the brief for respondents.
Before McGOWAN, TAMM and LEVENTHAL, Circuit Judges.
This case is one of two cases decided today involving the Food and Drug Administration's (FDA) withdrawal of approval of New Animal Drug Applications (NADA's) for diethylstilbestrol (DES). The instant case challenges FDA's disapproval of NADA's for DES feed premixes; the other case, Hess and Clark v. FDA, No. 73-1581 (consolidated with Vineland Laboratories v. FDA No. 73-1589), 161 U.S.App.D.C. ___, 495 F. 2d 975, involves implant pellets, the alternate dosage form of DES. Although these cases are not precisely the same, they contain several identical issues. Our disposition of the present case is governed by our extensive discussion in Hess and Clark. This opinion will be more brief—summarizing the background of the instant case, and the reasons for our disposition.
DES is a synthetic estrogen used to promote animal growth. The petitioners in the instant case manufacture DES in both liquid and dry form for mixture into feed for cattle and sheep. Typically, cattle are given the feed containing DES in a feed-lot for several weeks immediately prior to slaughter. It enables them to grow faster while using less feed, and while generating less solid waste. When used in this fashion, DES yields significant economic benefits for beef consumers.
This exception to the Delaney Clause recognizes the fact that DES passes out of an animal's system within a relatively short period. For that reason, if administration of DES ceases a sufficient time prior to slaughter, the slaughtered carcass will contain no DES residues.
Adhering to the provisions of the clause, the FDA allowed DES to be sold until 1973 because it never detected any disqualifying residues while using the "approved test method," the mouse-uterine test. In 1971, however, the U.S. Department of Agriculture began to test carcasses using a different method, a method that was not then and is not now an "approved test method." This testing revealed residues which USDA attributed to DES usage. Apparently, however, the USDA and FDA felt that these detected residues resulted from improper administration of DES for the FDA's response was to extend the required time period between cessation of DES administration to animals and slaughter of those animals.
Nonetheless, the USDA continued to detect residues after this change in the regulations. Accordingly, on June 21, 1972, the Commissioner issued a notice of intent to withdraw his approval of all NADA's for DES, and offered all interested NADA holders an opportunity for a hearing (37 Fed.Reg. 12,251). In the Notice, the Commissioner indicated his particular concern with the possibility of misuse of DES feed premixes, which are anonymous when added to feed. As noted in the Hess opinion, this Notice explicitly contemplated that it was a precursor to hearings to be held to investigate the nature of the DES problem.
Petitioners timely responded to the June, 1972, Notice, and requested hearings. The FDA, however, on August 4, 1972, refused the requests for hearing, and simultaneously withdrew its approval of the NADA's for feed premixes. (37 Fed.Reg. 15,747) In taking this action, the FDA relied upon test results received just prior to promulgation of the Order:
In turn, the Commissioner stated that these tests results, uncontroverted by any submitted alternative data, did not admit "the existence of a genuine and substantial issue of fact" so that no hearing need be held. Moreover, the Commissioner found that the test results compelled him to withdraw his approval of petitioners' NADA's:
This action is required under the strict terms of sections 512(d) (1) (H) and 512(e) (1)(B) of the act. These provisions, which contain the Delaney Clause, require that there be no detectable residue. The new USDA study clearly shows residues that are in the range of current detection methodology; new detection methodology is being developed that would be significantly more sensitive. Thus, under the law there is no alternative but to withdraw approval of the drug, even though there is no known public health hazard resulting from its use. (37 Fed.Reg. 15,749)
Although ordering an end to manufacture of premixes, the FDA allowed continued marketing of existing inventories until January 1, 1973. Id. Thereafter, on December 9, 1972, the FDA withdrew the regulations governing use of DES feed premixes, as required by statute. (37 Fed.Reg. 26,307) Petitioners appealed these Orders and their appeals are the subject of the instant case.
As in Hess, the petitioners argue that the challenged FDA order is legally defective because the FDA promulgated it without giving them a hearing. There are two means by which the approval of an existing NADA can be withdrawn without holding a hearing. (See Hess, at ___ __ ___, at 982-983 of 495 F.2d) First, the Secretary can suspend the approval on the basis of a finding that continued approval would present an imminent hazard to public health. Second, the summary judgment procedure may be invoked. In the instant case, the Commissioner expressly denied the presence of any public health hazard in the order of withdrawal. Instead, he relied on the summary judgment power. The issue is whether he properly invoked and executed the summary judgment procedure.
The first question is whether the FDA provided petitioners "due notice and opportunity for hearing" within the meaning of the statute, 21 U.S.C. § 360b(e) (1). The Commissioner argues that the only notice given to petitioners, in June 1972, meets the statutory requirement. In Hess we have noted several difficulties with the Commissioner's position. The principal difficulty is that the June 1972, Notice, "did not and could not contain any of the data on which the FDA relied in withdrawing its approval of the petitioner's NADA's". (Hess, at p....
To continue reading
Request your trial-
American Cyanamid Co. v. Food and Drug Administration
...21 U.S.C. § 355(d)(1) with 21 U.S.C. § 355(d)(5) . . .").46 See Hess & Clark, Inc. v. FDA, supra note 38; Chemetron Corp. v. HEW, 161 U.S.App.D.C. 415, 495 F.2d 995 (1974); E. R. Squibb & Sons, Inc. v. Weinberger, 483 F.2d 1382 (3d Cir. 1973); Dyestuffs & Chems, Inc. v. Flemming, 271 F.2d 2......
-
Hess & Clark, Division of Rhodia, Inc. v. Food & Drug Admin.
... ... WEINBERGER, Secretary, Department of Health, Education & Welfare, et al., Respondent ... os. 73-1581, 73-1589 ... United States Court of Appeals, District of Columbia ... Epstein, Atty., Dept. of Justice, were on the brief, for respondent ... " procedure was upheld in USV Pharmaceutical Corp. v. H. E. W., 151 U.S. App.D.C. 284, 466 F.2d 455 ... ...
-
Rhone-Poulenc, Inc., Hess & Clark Div. v. Food and Drug Admin.
...Columbia. Opinion PER CURIAM PER CURIAM: In Hess & Clark v. FDA, 161 U.S. App.D.C. 395, 495 F.2d 975 (1974) and Chemetron Corp. v. HEW, 161 U.S.App.D.C. 415, 495 F.2d 995 (1974), we held that the Commissioner of the Food and Drug Administration could not withdraw the agency's New Animal Dru......